- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.09. | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Guard Therapeutics International AB | 287 | GlobeNewswire | With effect from September 05, 2024, the subscription rights in Guard
Therapeutics International AB will be traded on First North Growth Market.
Trading will continue up until and including September... ► Artikel lesen | |
| GUARD THERAPEUTICS INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
| 02.09. | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.09.2024 | 353 | Xetra Newsboard | Das Instrument MSPA MA0000011488 ITISSALAT AL-MA. INH.DH 6 EQUITY wird cum Kapitalmassnahme gehandelt am 02.09.2024 und ex Kapitalmassnahme am 03.09.2024 The instrument MSPA MA0000011488 ITISSALAT AL-MA.... ► Artikel lesen | |
| 29.08. | Guard Therapeutics International AB: First patient dosed in Guard Therapeutics' phase 2b study POINTER | 139 | GlobeNewswire (Europe) | Guard Therapeutics today announced that the first patient has been dosed in the phase 2b clinical study POINTER with the drug candidate RMC-035 as a kidney-protective treatment in open-heart surgery.
"It... ► Artikel lesen | |
| 27.08. | Guard Therapeutics International AB: Guard Therapeutics carries out announced rights issue (repair issue) | 83 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, DISTRIBUTED OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 15.12.23 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 15.12.2023 | 917 | Xetra Newsboard | The following instruments on XETRA do have their first trading 15.12.2023 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 15.12.2023
Aktien
1 CA02255Q2099 Alvopetro Energy Ltd.
2... ► Artikel lesen | |
| 14.12.23 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 14.12.2023 | 665 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 14.12.2023Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 14.12.2023ISIN NameAT0000A1PY49 CLEEN... ► Artikel lesen | |
| 14.12.23 | XFRA ISIN CHANGE | 808 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen CA13646R5096 Canadian Palladium Resources Inc. 14.12.2023 CA74840A1066 Canadian Palladium Resources Inc. 15.12.2023... ► Artikel lesen |
7 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 53,90 | -0,63 % | Novonesis (Novozymes A/S): Trading by management and close relations of management | ||
| GENMAB | 193,35 | -0,10 % | Genmab A/S (GMAB): Among 12 High Growth Large Cap Stocks to Buy Now | ||
| ARBUTUS BIOPHARMA | 3,294 | +0,61 % | Arbutus Biopharma Corporation: Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon | 50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,360 | 0,00 % | Moleculin Biotech erzielt Fortschritte im Annamycin-AML-Studienprotokoll | ||
| VERICEL | 53,50 | -1,83 % | Vericel Corporation: Vericel Reports Third Quarter 2024 Financial Results | Total Revenue Growth of 27% to $57.9 Million Gross Margin of 72% and Adjusted EBITDA Growth of 84% Full-Year Profitability Guidance Raised FDA Approval and Commercial Launch of MACI Arthro in Third... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,530 | -4,64 % | BioXcel Therapeutics-Aktie erreicht 52-Wochen-Tief bei 0,50 US-Dollar | ||
| SENSEI BIOTHERAPEUTICS | 0,483 | +4,09 % | Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - ... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 1,215 | -0,41 % | MustGrow Biologics Corp.: MustGrow Provides 2024 Pipeline Update | MustGrow transitions from R&D to commercialization.TerraSanteTM biofertility product manufacturing and sales has commenced, with potential initial sales ramp-up in 2025 and 2026.Commercialization of... ► Artikel lesen | |
| REGENXBIO | 8,850 | -3,28 % | Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy | ||
| AKEBIA | 1,681 | -1,35 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025
Over 300,000 patients, representing approximately 60% of dialysis patient... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 4,340 | +10,71 % | Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update | ~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments... ► Artikel lesen | |
| REVANCE THERAPEUTICS | 3,660 | +1,10 % | Revance Therapeutics gains as Crown Labs further extends tender offer | ||
| ZEVRA THERAPEUTICS | 8,300 | -2,35 % | ZVRA-Aktie erreicht 52-Wochen-Hoch bei 9,09 US-Dollar | ||
| CORVUS PHARMACEUTICALS | 7,800 | -0,38 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis | Adds to growing body of evidence supporting the potential of ITK inhibition as a novel therapeutic for the treatment of a wide range of immune diseases Data will be presented in a poster at ACR Convergence... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 16,700 | 0,00 % | Cartesian Therapeutics (NASDAQ:RNAC) Shares Gap Up - What's Next? |
Das Unternehmen GUARD THERAPEUTICS INTERNATIONAL AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,610 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GUARD THERAPEUTICS INTERNATIONAL AB finden Sie auf Wallstreet Online.
